Orsenix Holdings BV

Syros Pharmaceuticals, Inc. significantly extended its financial runway through three concurrent transactions on 5 July that are expected to fund company operations into 2025 and get it well past the

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck & Co. Seeks NASH Momentum From Al

Launched on the public markets four years ago as a developer of medicines targeting gene expression conditions, Syros Pharmaceuticals has struggled to convince investors of its strategy. Syros’s sha